Hello, everyone, and how are you today? We hope the weekend was refreshing and invigorating. Now, though, the time has come to resume the usual routine of meetings and deadlines. Our own schedule, however, will be interrupted today for a meeting and so a colleague will handle some of the usual responsibilities until our return. Nonetheless, you can always send us interesting items regardless. Meanwhile, here are some tidbits to help you start the week. Hope your day goes well and do stay in touch...
Novartis And Penn Strike Deal On Cancer Research (New York Times)
Momenta Set Back As Court Lifts Ban On Rival Bloodthinner (Reuters)
FDA OKs Sanofi & Regneron Colon Cancer Drug (Associated Press)
China Issues New Rules On Excipients (Xinhuanet)
FDA Approves First Version Of Merck's Singulair (Reuters)
Ireland Looks To Cut Generic Costs (Irish Times)
Was MedImmune Worth $16.5 Billion? (Washington Post)
UK Drug Price Negotiations To Begin Next Month (Reuters)
Sun Pharma Considers Internal Restructuring (Economic Times)
EDITOR'S NOTE: Please check this post for updates during the day
2 Comments